MRVI
Maravai LifeSciences Holdings, Inc. NASDAQ Listed Nov 20, 2020$5.20
-0.38%
vs $5.22
Mkt Cap $754.4M
52w Low $2.01
99.4% of range
52w High $5.22
50d MA $4.23
200d MA $3.51
P/E (TTM)
-5.7x
EV/EBITDA
—
P/B
2.0x
Debt/Equity
0.2x
ROE
-61.6%
P/FCF
-10.7x
RSI (14)
68.50
ATR (14)
$0.26
Beta
0.43
50d MA
$4.23
200d MA
$3.51
Avg Volume
3.2M
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
10770 Wateridge Circle · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.05 | 0.01 | +120.0% | 3.94 | +11.4% | +23.1% | -2.3% | -1.7% | -6.2% | -1.8% | — |
| Feb 25, 2026 | AMC | -0.07 | -0.04 | +42.9% | 3.26 | +9.8% | +9.2% | +0.0% | +1.4% | +2.2% | +3.5% | — |
| Nov 6, 2025 | AMC | -0.06 | -0.08 | -33.3% | 2.89 | -11.8% | -0.7% | +8.0% | +4.8% | +0.0% | +0.0% | — |
| Aug 11, 2025 | AMC | -0.06 | -0.08 | -33.3% | 2.06 | +13.1% | +30.6% | +2.2% | -5.5% | +0.4% | -1.5% | — |
| May 12, 2025 | AMC | -0.07 | -0.08 | -14.3% | 2.12 | +0.0% | -2.8% | -3.9% | -1.0% | +7.1% | +3.3% | — |
| Mar 18, 2025 | AMC | -0.03 | -0.06 | -100.0% | 2.58 | -0.8% | -5.8% | -1.2% | -5.4% | -1.3% | +2.7% | — |
| Nov 7, 2024 | AMC | -0.01 | -0.02 | -150.0% | 7.84 | -39.4% | -35.2% | +13.8% | -1.4% | -1.2% | -7.6% | — |
| Aug 7, 2024 | AMC | -0.04 | -0.08 | -100.0% | 9.10 | -5.4% | -6.8% | +0.7% | +1.9% | -3.0% | -2.6% | — |
| May 8, 2024 | AMC | -0.02 | -0.02 | -21.3% | 8.87 | +3.2% | +11.2% | +6.1% | +0.7% | +1.6% | +4.7% | — |
| Feb 22, 2024 | AMC | 0.00 | 0.01 | +185.2% | 5.11 | +36.0% | +63.6% | -3.9% | +2.9% | -2.9% | -3.6% | — |
| Nov 7, 2023 | AMC | -0.00 | -0.01 | -257.1% | 6.88 | -11.0% | -31.7% | +0.0% | +9.1% | -3.5% | +4.4% | — |
| Aug 7, 2023 | AMC | -0.03 | -0.06 | -100.0% | 11.02 | -14.2% | +0.7% | -3.2% | -4.2% | +0.4% | -2.8% | — |
| May 8, 2023 | AMC | 0.04 | 0.03 | -17.1% | 13.90 | -10.9% | -13.0% | +0.2% | +13.0% | +8.3% | +1.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $3.60 | $3.64 | +1.1% | +1.9% | -2.2% | -3.6% | +1.7% | -2.6% |
| Aug 12 | RBC Capital | Maintains | Outperform → Outperform | — | $2.06 | $2.33 | +13.1% | +30.6% | +2.2% | -5.5% | +0.4% | -1.5% |
| Aug 12 | Craig-Hallum | Maintains | Buy → Buy | — | $2.06 | $2.33 | +13.1% | +30.6% | +2.2% | -5.5% | +0.4% | -1.5% |
| May 13 | Baird | Maintains | Neutral → Neutral | — | $2.12 | $2.12 | +0.0% | -2.8% | -3.9% | -1.0% | +7.1% | +3.3% |
| May 13 | Craig-Hallum | Maintains | Buy → Buy | — | $2.12 | $2.12 | +0.0% | -2.8% | -3.9% | -1.0% | +7.1% | +3.3% |
| Mar 25 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.24 | $2.25 | +0.4% | +2.7% | +3.0% | -0.8% | +0.4% | -6.4% |
| Mar 21 | UBS | Maintains | Neutral → Neutral | — | $2.40 | $2.12 | -11.7% | -5.4% | -1.3% | +2.7% | +3.0% | -0.8% |
| Mar 3 | BofA Securities | Maintains | Buy → Buy | — | $3.22 | $3.20 | -0.6% | -6.2% | -6.0% | -1.1% | -5.0% | +10.9% |
| Feb 26 | Baird | Downgrade | Outperform → Neutral | — | $3.14 | $3.06 | -2.5% | +3.5% | -6.2% | +5.6% | -6.2% | -6.0% |
| Dec 5 | Goldman Sachs | Downgrade | Neutral → Sell | — | $5.42 | $5.18 | -4.4% | -6.1% | -0.8% | +7.5% | +9.2% | -2.7% |
| Nov 8 | William Blair | Downgrade | Outperform → Market Perform | — | $7.84 | $4.75 | -39.4% | -35.2% | +13.8% | -1.4% | -1.2% | -7.6% |
| Nov 8 | RBC Capital | Maintains | Outperform → Outperform | — | $7.84 | $4.75 | -39.4% | -35.2% | +13.8% | -1.4% | -1.2% | -7.6% |
| Nov 8 | Baird | Maintains | Outperform → Outperform | — | $7.84 | $4.75 | -39.4% | -35.2% | +13.8% | -1.4% | -1.2% | -7.6% |
| Oct 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.83 | $7.74 | -1.1% | -1.9% | +0.1% | -0.8% | +5.0% | +3.1% |
| Aug 16 | RBC Capital | Maintains | Outperform → Outperform | — | $7.97 | $7.98 | +0.1% | +21.5% | -4.5% | -2.7% | -2.3% | +0.9% |
| Aug 13 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $8.70 | $8.30 | -4.6% | -3.0% | -2.6% | -3.0% | +21.5% | -4.5% |
| Aug 8 | UBS | Maintains | Neutral → Neutral | — | $9.10 | $8.61 | -5.4% | -6.8% | +0.7% | +1.9% | -3.0% | -2.6% |
| Aug 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $9.10 | $8.61 | -5.4% | -6.8% | +0.7% | +1.9% | -3.0% | -2.6% |
| Jul 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.35 | $7.35 | +0.0% | +3.0% | +2.0% | +11.4% | +4.0% | -2.0% |
| May 9 | Baird | Maintains | Outperform → Outperform | — | $8.87 | $9.15 | +3.2% | +11.2% | +6.1% | +0.7% | +1.6% | +4.7% |
| Feb 23 | Stifel | Maintains | Buy → Buy | — | $5.11 | $6.95 | +36.0% | +63.6% | -3.9% | +2.9% | -2.9% | -3.6% |
| Feb 23 | RBC Capital | Maintains | Outperform → Outperform | — | $5.11 | $6.95 | +36.0% | +63.6% | -3.9% | +2.9% | -2.9% | -3.6% |
| Dec 12 | BofA Securities | Upgrade | Neutral → Buy | — | $5.15 | $5.41 | +5.0% | +8.5% | +6.1% | +5.2% | -0.2% | +0.0% |
| Nov 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $4.70 | $4.76 | +1.3% | +0.0% | +9.1% | -3.5% | +4.4% | +0.4% |
| Nov 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $4.70 | $4.76 | +1.3% | +0.0% | +9.1% | -3.5% | +4.4% | +0.4% |
| Aug 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $11.10 | $11.12 | +0.2% | -3.2% | -4.2% | +0.4% | -2.8% | +3.3% |
| Aug 8 | KeyBanc Capital Markets | Downgrade | Overweight → Sector Weight | — | $11.02 | $9.45 | -14.2% | +0.7% | -3.2% | -4.2% | +0.4% | -2.8% |
| Aug 8 | Baird | Maintains | Outperform → Outperform | — | $11.02 | $9.45 | -14.2% | +0.7% | -3.2% | -4.2% | +0.4% | -2.8% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $11.02 | $9.45 | -14.2% | +0.7% | -3.2% | -4.2% | +0.4% | -2.8% |
| Aug 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $11.02 | $9.45 | -14.2% | +0.7% | -3.2% | -4.2% | +0.4% | -2.8% |
| Aug 8 | Credit Suisse | Maintains | Neutral → Neutral | — | $11.02 | $9.45 | -14.2% | +0.7% | -3.2% | -4.2% | +0.4% | -2.8% |
| Aug 8 | Deutsche Bank | Maintains | Buy → Buy | — | $11.02 | $9.45 | -14.2% | +0.7% | -3.2% | -4.2% | +0.4% | -2.8% |
| May 23 | Credit Suisse | Downgrade | Outperform → Neutral | — | $13.60 | $12.88 | -5.3% | +0.3% | -1.8% | -1.3% | -1.3% | -0.3% |
| May 10 | Goldman Sachs | Maintains | Neutral → Neutral | — | $12.09 | $12.37 | +2.3% | +0.2% | +13.0% | +8.3% | +1.1% | -10.7% |
| May 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $12.09 | $12.37 | +2.3% | +0.2% | +13.0% | +8.3% | +1.1% | -10.7% |
| May 9 | Goldman Sachs | Downgrade | Buy → Neutral | — | $13.90 | $12.39 | -10.9% | -13.0% | +0.2% | +13.0% | +8.3% | +1.1% |
| May 9 | Credit Suisse | Maintains | Outperform → Outperform | — | $13.90 | $12.39 | -10.9% | -13.0% | +0.2% | +13.0% | +8.3% | +1.1% |
| May 9 | RBC Capital | Maintains | Outperform → Outperform | — | $13.90 | $12.39 | -10.9% | -13.0% | +0.2% | +13.0% | +8.3% | +1.1% |
| May 9 | Deutsche Bank | Maintains | Buy → Buy | — | $13.90 | $12.39 | -10.9% | -13.0% | +0.2% | +13.0% | +8.3% | +1.1% |
| Feb 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $14.96 | $14.61 | -2.3% | -4.0% | +0.6% | +2.1% | +1.5% | +5.3% |
| Feb 23 | Baird | Maintains | Outperform → Outperform | — | $13.83 | $16.31 | +17.9% | +8.2% | -4.0% | +0.6% | +2.1% | +1.5% |
| Feb 23 | Credit Suisse | Maintains | Outperform → Outperform | — | $13.83 | $16.31 | +17.9% | +8.2% | -4.0% | +0.6% | +2.1% | +1.5% |
| Feb 23 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $13.83 | $16.31 | +17.9% | +8.2% | -4.0% | +0.6% | +2.1% | +1.5% |
| Jan 17 | Goldman Sachs | Maintains | Buy → Buy | — | $13.83 | $13.74 | -0.7% | -0.4% | +1.9% | -0.5% | +0.6% | +3.3% |
| Jan 5 | UBS | Downgrade | Buy → Neutral | — | $13.98 | $13.24 | -5.3% | -5.2% | -0.7% | -1.4% | +5.1% | +2.6% |
| Dec 14 | Deutsche Bank | Maintains | Buy → Buy | — | $14.27 | $14.58 | +2.2% | +6.0% | -0.8% | -1.5% | -3.7% | -0.1% |
| Dec 7 | RBC Capital | Maintains | Outperform → Outperform | — | $12.50 | $12.73 | +1.8% | +1.7% | +4.6% | -0.2% | +0.2% | +7.3% |
| Nov 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $14.51 | $15.50 | +6.8% | +6.9% | -8.7% | +0.6% | -5.5% | +9.3% |
| Nov 4 | Goldman Sachs | Maintains | Buy → Buy | — | $14.51 | $15.50 | +6.8% | +6.9% | -8.7% | +0.6% | -5.5% | +9.3% |
| Nov 3 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $15.36 | $13.49 | -12.2% | -5.5% | +6.9% | -8.7% | +0.6% | -5.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | ORESHACK KURTOff | General Counsel | Sell | 25,000 | $5.10 | $128K | 335,767 | +2.56% | +4.19% |
| Jun 9, 2026 | ORESHACK KURTOff | General Counsel | Sell | 25,000 | $5.06 | $126K | 360,767 | +2.56% | +4.19% |
8-K · 1.01
! Medium
Maravai LifeSciences Holdings, Inc. -- 8-K 1.01: Financing / Debt Agreement
Maravai LifeSciences secured a $150 million credit facility, providing additional financial flexibility for operations and strategic initiatives.
Jun 3
8-K
Maravai LifeSciences Holdings, Inc. -- 8-K Filing
May 29
8-K · 2.02
!! High
Maravai LifeSciences Holdings, Inc. -- 8-K 2.02: Earnings Results
Maravai LifeSciences reported Q1 2026 financial results, providing investors with updated performance metrics and operational guidance for the nucleic acid production company.
May 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An experienced life sciences executive is joining one of these companies, likely signaling leadership transition or strategic expansion in biotech/pharma sectors, which could impact growth direction and investor confidence.
Apr 7
8-K
Maravai LifeSciences Holdings, Inc. -- 8-K Filing
Maravai LifeSciences announced Q4 2025 results with organizational restructuring and ahead-of-plan cost reductions, signaling management's commitment to operational efficiency and profitability improvement.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Braidwell Lp | 8,353,287 | $27M | — | Dec 2025 |
| 2 | Morgan Stanley | 6,893,604 | $22M | Added | Dec 2025 |
| 3 | Vanguard Capital Management Llc | 5,449,702 | $15M | New | Mar 2026 |
| 4 | First Eagle Investment Management, Llc | 5,048,672 | $14M | Added | Mar 2026 |
| 5 | Renaissance Technologies Llc | 4,264,689 | $12M | Added | Mar 2026 |
| 6 | Monaco Asset Management Sam | 3,460,190 | $11M | Reduced | Dec 2025 |
| 7 | Tejara Capital Ltd | 3,495,187 | $10M | Added | Mar 2026 |
| 8 | Point72 Asset Management | 3,205,496 | $9M | Added | Mar 2026 |
| 9 | Marshall Wace, Llp | 2,081,334 | $6M | Added | Mar 2026 |
| 10 | Millennium Management | 1,649,490 | $5M | Reduced | Mar 2026 |
| 11 | Two Sigma Investments, Lp | 1,579,840 | $4M | Added | Mar 2026 |
| 12 | Jane Street Group, Llc | 1,295,058 | $4M | Added | Dec 2025 |
| 13 | Systematic Financial Management Lp | 1,484,539 | $4M | Reduced | Mar 2026 |
| 14 | Citadel Advisors Llc | 1,484,319 | $4M | Added | Mar 2026 |
| 15 | Northern Trust Corp | 1,110,914 | $3M | Added | Mar 2026 |
| 16 | Vanguard Portfolio Management Llc | 952,838 | $3M | New | Mar 2026 |
| 17 | First Pacific Advisors, Lp | 884,883 | $3M | — | Mar 2026 |
| 18 | Citigroup Inc | 522,042 | $2M | Added | Dec 2025 |
| 19 | Bank Of America Corp /de/ | 582,211 | $2M | Reduced | Mar 2026 |
| 20 | Tudor Investment Corp | 396,915 | $1M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$754.4M
Enterprise Value
$567.6M
P/E (TTM)
-5.71x
Forward P/E
—
PEG Ratio
0.27x
P/B
2.02x
P/S
4.06x
P/FCF
-10.67x
EV/EBITDA
—
Shares Out
145.1M
Financials (TTM)
Revenue
$185.7M
Net Income
-$130.8M
EBITDA
-$147.1M
Free Cash Flow
-$70.7M
Op Cash Flow
-$57.6M
EPS Basic
$-0.91
EPS Diluted
$-0.91
EPS Forward
$-0.18
Gross Margin
18.0%
Op Margin
-3.6%
Net Margin
-70.4%
Balance Sheet
Total Assets
$770.6M
Total Liab.
$397.9M
Total Equity
$372.7M
Cash
$216.9M
LT Debt
$30.1M
Book Value/Sh
$2.57
Debt/Equity
0.17x
Current Ratio
6.60
Quick Ratio
5.69
Returns & Growth
ROE
-61.6%
ROA
-17.0%
ROIC
-0.9%
Rev Growth YoY
-28.3%
EPS Growth YoY
+13.3%
Price Returns
2W
+11.9%
1M
+30.4%
3M
+34.8%
6M
+32.6%
12M
+113.3%
Technicals
52W High
$5.22
52W Low
$2.01
50d MA
$4.23
200d MA
$3.51
RSI (14)
68.50
ATR (14)
$0.26
Beta
0.43
Avg Volume
3.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$4.50
High
$4.50
Low
$4.50
Median
$4.50
Data updated apr 26, 2026 1:19pm
· Source: financialmodelingprep.com